1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow HER2 Expression: new trials by email Literature Review of HER2 Expression trials Research Report on HER2 Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
RC48 antibody (1) · disitamab vedotin (1) · toripalimab (1)
RenJi Hospital (1)
China (1)
Haige Chen (1)